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Cryptococcal immune reconstitution inflammatory syndrome (C-IRIS) in HIV-infected patients presents as a clinical
worsening or new presentation of cryptococcal disease as a result of anti-retroviral therapy mediated immune
restoration. Recurrent C-IRIS is a rare condition. Recently, recurrent C-IRIS involving the central nervous system,
which is thought to require prolonged or alternative immunosuppressive therapy, has been described. Here, we
present an unusual case of recurrent C-IRIS, sequentially involving the central nervous system and lymph nodes, in
an HIV-infected patient after anti-retroviral therapy. While corticosteroids were used to control the inflammatory
cerebral cryptococcomas, lymphadenitis that developed after cessation of corticosteroids resolved without
additional immunosuppressive or anti-inflammatory drugs. This case suggests the possibility of site-specific recovery
of pathogen-specific immune response after anti-retroviral therapy. In this condition, each episode of C-IRIS may be
treated independently, and extended corticosteroids may not always be needed.
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Cryptococcal immune reconstitution inflammatory syn-
drome (C-IRIS) presents as a clinical worsening or new
presentation of cryptococcal disease after rapid immune
restoration. In patients with human immunodeficiency
virus (HIV)-1 infection, this immune restoration is
driven by anti-retroviral therapy (ART). HIV-associated
C-IRIS occurs in two forms: 1) paradoxical C-IRIS in pa-
tients diagnosed with cryptococcosis before ART who
initially respond to antifungal therapy but then deterior-
ate or develop new clinical disease associated with ART-
mediated immune restoration; 2) unmasking C-IRIS in
patients who present with a first episode of cryptococcal
disease with atypical inflammatory manifestations after
ART [1,2].
The most common manifestation of HIV-associated C-
IRIS is meningitis, accounting for around 70% of cases [1].
Lymphadenopathy as well as cerebral lesions have also
been described [1]. Although C-IRIS occurs in 8 to 49% of* Correspondence: henanyyf@hotmail.com
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stated.HIV-infected patients with cryptococcal disease who initi-
ate ART [1], recurrent C-IRIS is a rare condition. Recently,
worsening of central nervous system (CNS) C-IRIS after
cessation or tapering of corticosteroids has been described
in 3 case reports [3-5]. The patients were successfully
treated with additional courses of corticosteroids or other
immunomodulatory drugs such as adalimumab or thalido-
mide [3-5]. This form of recurrent C-IRIS appears to be as-
sociated with an unusual inflammatory reaction that
requires prolonged or alternative immunosuppressive ther-
apy. Here, we present an unusual case of recurrent C-IRIS,
sequentially involving CNS and lymph nodes, in an HIV-
infected patient after ART. While corticosteroids were
used to control the inflammatory cerebral cryptococcomas,
the lymphadenitis that developed after cessation of cortico-
steroids resolved without additional immunosuppressive or
anti-inflammatory drugs.
Case report
A 19-year-old HIV-1-infected man was admitted to our
hospital in late July 2011 because of fever and headache
for two weeks and confusion for 4 days. His CD4 cell
count was 0 cell/μL. Soon after his admission, he wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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fluid (CSF) analysis demonstrated a white blood cell count
of 32 cells/mm3, a glucose level of 1.4 mmol/L, a total pro-
tein level of 993.4 mg/L, and a positive India ink stain re-
sult. The baseline CSF fungal cell count under microscopy
was 70 yeasts/μL. CSF and blood cultures were positive for
Cryptococcus spp. Brain magnetic resonance imaging
(MRI) revealed bilateral basal ganglia abnormalities con-
sistent with cerebral cryptococcomas (Figure 1A, B). As
per recommended clinical practice guidelines, he was
treated with amphotericin B (AmB, 0.7 mg/kg per day
intravenously) plus flucytosine (100 mg/kg per day in 4 di-
vided doses) for 11 weeks, followed by fluconazole (400 mg
per day) maintenance therapy [6]. CSF culture was sterile
two weeks after initiation of anti-cryptococcal treatment.
Follow-up lumbar puncture six weeks after initiation of
anti-cryptococcal treatment revealed an improved CSF pro-
file (white blood cell count of 2cells/mm3, a glucose level of
2.9 mmol/L and a total protein level of 147.8 mg/L). ART
with lamivudine, stavudine and efavirenz was introduced in
September 2011, after six weeks on anti-cryptococcal treat-
ment. A follow-up brain MRI, obtained 7 weeks after
initiation of anti-cryptococcal therapy revealed partial reso-
lution of the cerebral cryptococcomas (Figure 1C). The
patient was asymptomatic and discharged. Another brain
MRI in February 2012 demonstrated near complete
resolution of the cerebral cryptococcomas (see Additional
file 1).Figure 1 Brain MRI of the patient. Axial T2-FLAIR imaging obtained soon
basal ganglia (arrows in A) without enhancement (B). After 7 weeks on ant
of the lesion (arrows in C). Twenty-five weeks after initiation of anti-retroviral
images showed abnormal hyperintensities in bilateral basal ganglia again (arro
on corticosteroids and intensified anti-cryptococcal therapy, T2-FLAIR imagesIn March 2012, when the patient returned for a follow
up visit in clinic, recurrent cerebral cryptococcomas
(Figure 1D, E) were detected despite fluconazole prophy-
laxis (400 mg per day) and undetectable plasma HIV
viral load with a CD4 cell count of 52 cells/μL. At that
time, he was asymptomatic. CSF analysis demonstrated a
white blood cell count of 11 cells/mm3, glucose level of
1.9 mmol/L, total protein level of 1260.2 mg/L, negative
India ink stain and negative culture. CSF was further ex-
amined by a pathologist, and fungal cells as well as
tumor cells were not identified. An interferon-gamma
release assay (T-SPOT.TB) was also negative. Extensive
laboratory studies revealed no active infection, including
negative anti-toxoplasma antibody and undetectable
cytomegalovirus viral load from the CSF and blood, al-
though CSF cryptococcal antigen (CRAG) titer was 1:4
and serum CRAG titer 1:8. The recurrence of cerebral
cryptococcomas was considered C-IRIS. The patient was
observed without changing his treatment until he devel-
oped headache and dizziness in May 2013. At that point,
anti-cryptococcal therapy was intensified with AmB, vor-
iconazole (200 mg every 12 hours) and flucytosine for
6 weeks, followed by fluconazole (400 mg per day) main-
tenance therapy. ART was changed to lamivudine, teno-
fovir and raltegravir out of concern for drug interactions
between voriconazole and efavirenz. Corticosteroids
were co-administered and slowly tapered off over
6 months. His CD4 cell count increased to 108 cells/μL.after admission showed abnormal hyperintensities in the bilateral
i-cryptococcal therapy, axial T2-FLAIR images showed partial resolution
therapy and while on fluconazole maintenance therapy, axial T2-FLAIR
ws in D) with irregular patchy enhancement (arrows in E). After 19 days
showed near complete resolution of brain lesions (F).
Figure 2 Brain MRI of the patient after cessation of corticosteroid. Axial T2-FLAIR images showed new cerebral lesions (arrows in A). After
16 days on intensified anti-cryptococcal therapy, T2-FLAIR demonstrated near complete resolution of cerebral lesions (B).
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lution of the brain lesions (Figure 1F).
In December 2012, about 15 months after initiation of
ART and while still on fluconazole maintenance therapy, a
brain MRI demonstrated new brain lesions mainly involv-
ing the left temporal lobe (Figure 2A). CSF analysis dem-
onstrated a white blood cell count of 4 cells/mm3, glucose
level of 2.7 mmol/L, total protein level of 258 mg/L, nega-
tive India ink stain, negative cryptococcal antigen test and
negative culture result. However, serum CRAG titer in-
creased to ≥1:32. Despite undetectable plasma HIV viral
load, his CD4 count decreased to 57 cells/μL. After re-
intensification of anti-cryptococcal therapy with AmB,Figure 3 Imaging and histological studies of the lymphadenopathy. C
trachea compression due to mediastinal lymphadenopathy (arrow in A and
granulomatous inflammation (arrows in C, haematoxylin and eosin stain, m
magnification × 400). After 1 month of observation, repeat CT scan confirmvoriconazole and flucytosine for 19 days, to which the
brain lesion responded favorably (Figure 2B), the patient
developed a new, tender, protruding mass in the right
neck in January 2013. The combination antifungal therapy
was used for 6 weeks, followed by voriconazole (200 mg
every 12 hours) for maintenance therapy. The mass did
not improve with addition of amoxicillin/sulbactam and
continued to progress. Subsequently, the patient com-
plained of fever and cough. A computed tomography (CT)
scan, obtained about eight weeks after re-intensification of
anti-cryptococcal therapy, showed a mass in the right neck
with compression of the trachea due to mediastinal
lymphadenopathy (Figure 3A and B). A biopsy of theT scan showing right cervical mass measuring 48 × 73 mm and
B respectively). Biopsy of the cervical mass revealed necrotizing
agnification × 40) and fungal structures (arrows in D, Alcian blue stain,
ed partial resolution of lymphadenopathy (arrows in E and F).
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tizing granulomatous inflammation (Figure 3C and D).
Acid-fast bacilli were not identified in the biopsy speci-
men. Fungal culture of the biopsy specimen was negative.
The patient refused corticosteroids because of adverse ef-
fects including weight gain and purple striae, and no new
immunosuppressive or anti-inflammatory drugs were
used. With anti-fungal therapy, the lymphadenopathy fi-
nally resolved (Figure 3E and F). In May 2013, the patient
did not have any clinical manifestations associated with
cryptococcal infection. The patient, who most recently
had a CD4 cell count of 223 cells/μL in October 2013, has
been closely followed and is asymptomatic.
Discussions
Although there is no well-established diagnostic test for
C-IRIS, useful consensus definitions published by the
International Network for the Study of HIV-associated
IRIS (INSHI) can be used to evaluate suspected cases
[1]. These case definitions have been widely accept in
primary studies for C-IRIS [7-9] and are readily used in
our clinical practice. According to INSHI’s case defini-
tions, encephalitis and/or meningitis with a negative
CSF culture result and positive CSF cryptococcal antigen
could be due to C-IRIS. Positive empiric response to
corticosteroids further supports this diagnosis. Despite
intensification of his anti-cryptococcal treatment, lymph-
adenitis occurred and continued to progress for a long
time. Although cryptococcal elements were indentified
in an inflamed lymph node, the biopsy culture was nega-
tive. Moreover, CSF analysis at the time the patient de-
veloped cryptococcal lymphadenitis was negative for
cryptococcal elements, suggesting a very positive re-
sponse to anti-cryptococcal therapy. Therefore, excessive
inflammation observed in C-IRIS may be a contributing
factor to lymphadenitis.
The pathogenesis of C-IRIS is still incompletely under-
stood. Restoration of pathogen specific immune response
after ART is thought to cause immunopathological lesions
in tissues infected by that pathogen [10]. Nevertheless,
CD4 cell counts are not included in the criteria for
INSHI’s case definitions [1], as the number of CD4 cells
measured in the periphery does not reflect the function
and number of CD4 cells at the site of an opportunistic
infection. Similarly, the recurrent C-IRIS sequentially in-
volving CNS and lymph nodes implies the possibility
of site-specific recovery of pathogen specific immune
response. Unlike the management of the previously
described recurrent C-IRIS that was more clearly regarded
as a corticosteroid-dependent C-IRIS [3-5], the recurrent
C-IRIS sequentially involving different sites may not
always require extended corticosteroid therapy. Each epi-
sode of C-IRIS of this recurrent form may be treated
independently.Conclusion
In conclusion, we present a case of recurrent C-IRIS, se-
quentially involving central nervous system and lymph
nodes, in an HIV-infected patient after anti-retroviral
therapy. This case suggests the possibility of site specific
recovery of pathogen specific immune response after
anti-retroviral therapy. In this condition, each episode of
C-IRIS may be treated independently, and extended cor-
ticosteroid therapy may not always be needed.
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